The Effect of Anticancer Drug Sequence in Experimental Combination Chemotherapy

References

• DeVita VT, Young RC, Canellos GP. Combinations versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975; 35: 98–110
   PubMed Web of Science ®Google Scholar
• Capizzi RL, Keiser LW, Sartorelli AC. Combination chemotherapy—Theory and practice. Semin Oncol 1977; 4(2)227–253
   PubMed Web of Science ®Google Scholar
• Goldin A. Combined chemotherapy. Oncology 1980; 37: 3–8, Suppl
   PubMed Web of Science ®Google Scholar
• Salmon SE, Silvestrini R, Alberts DS, et al. Methods for testing sensitivity of human tumors to anticancer drugs Current Chemotherapy Immunotherapy. Proc 12th Intl Congr Chemother. Florence, Italy. Amer Soc for Microbiol, Washington. D.C. 1982; 125–130
   Google Scholar
• Salmon SE. Applications of the human tumor stem cell assay to new drug evaluation and screening. Cloning of Human Tumor Stem Cells, SE. Salmon. Alan R Liss, New York 1980; 291–314
   Google Scholar
• Salmon SE, Meyskens FL, Jr., Alberts DS, et al. New drugs in ovarian cancer and malignant melanoma: In vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep 1981; 65: 1–12
   PubMedGoogle Scholar
• Salmon SE, Liu RM, Casazza AM. Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol 1981; 6: 103–110
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Coltman CA, Forseth B. Activity of mitoxantrone in a human tumor cloning system. Cancer Res 1981; 41: 1853–1855
   PubMed Web of Science ®Google Scholar
• Salmon SE, Durie BGM, Young L, et al. Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1983; 1(3)217–225
   PubMed Web of Science ®Google Scholar
• Shoemaker RH, Wolpert-DeFilipes MK, Kern DH, et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985; 45: 2145–2153
   PubMed Web of Science ®Google Scholar
• Bertino JR., Sawicki WL, Linquist C, et al. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 1977; 271: 327–328
   Google Scholar
• Rivera G, Avery T, Roberts D. Response of L-1210 to combinations of cytosine arabinoside and VM-26 or VP-16-213. Eur J Cancer 1975; 11: 639–647
   PubMed Web of Science ®Google Scholar
• Drewinko B, Loo TL, Brown B, et al. Combination chemotherapy in vitro and adriamycin observations of additive, antagonistic and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys 1976; 1: 187–195
   PubMedGoogle Scholar
• Matsushima Y, Kdnzawa F, Hoshi A, et al. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 1985; 14: 104–107
   PubMed Web of Science ®Google Scholar
• Ludwig R, Alberts DS, Miller TP, et al. Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay. Cancer Chemother Pharmacol 1984; 12: 135–141
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Moore GE, Yagi Y, et al. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma (32327). Proc Exp Soc Med Biol 1967; 125: 1246–1250
   PubMed Web of Science ®Google Scholar
• Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 1972; 114: 1012–1019
   PubMed Web of Science ®Google Scholar
• Salmon SE, Hamburger AW, Soehnlen B, et al. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978; 24: 1321–1327
   Google Scholar
• Alberts DS, Salmon SE, Chen H-SG, et al. Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol 1981; 6: 253–261
   PubMed Web of Science ®Google Scholar
• Salmon SE, Young L, Lebowitz J, et al. Evaluation of an automated image analysis system for counting human tumor colonies. Int J Cell Cloning 1984; 2: 142–160
   PubMedGoogle Scholar
• Chou TC, Talaly P. Quantitation analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. J Theor Biol 1976; 59: 253–276
   PubMed Web of Science ®Google Scholar
• Drewinko B, Novak JK, Barranco SC. The response of human lymphoma cells in vitro to bleomycin and 1,3-bis(2-chloroethyl)-I-nitrosourea. Cancer Res 1972; 32: 1206–1208
   PubMed Web of Science ®Google Scholar
• Samuels ML, Holoye PY, Johnson DE. Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer 1975; 36: 318–326
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Greco FA, Williams SD, . VP-16 in the treatment of refractory germinal neoplasms. Etoposide (VP-16): Current Status and New Developments, BF. Issell, FM. Hluggia, SK. Carter, et al. Academic Press, New York 1984; 243–252
   Google Scholar
• Gewirtz AM, Cadman E. Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancer. Cancer 1981; 47: 2552–2555
   PubMed Web of Science ®Google Scholar
• Rivera G, Dahl GV, Bowman WP, et al. Prolonged second marrow remission in children with lymphocytic leukeniia (ALL) treated with VM-26 and cytosine arabinoside (ARA-C). Proc Am Assoc Cancer Res ASCO. 1981; 22: 481
   Google Scholar
• Skipper HE, Schabel FM, Jr, Wilcox LS. Experimental evaluation of potential anticancer agents. XXI. Scheduling of ardbinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother Rep 1967; 51: 126–165
   Google Scholar
• Sirotnak FM, Schmid FA, Temple C, Jr, et al. Optimum scheduling during combination chemotherapy of murine leukemia. Cancer Chemother Pharmacol 1983; 11: 205–207
   PubMedGoogle Scholar
• Rose WC, Bradner WT. In vivo experimental antitumor activity of etoposide. Etoposide (VP-16): Current Status and New Developments, BF. Issell, FM. Muggia, SK. Carter. Academic Press, New York 1984; 33–47
   Google Scholar
• Carlson RW, Sikic B. I: Continuous infusion or bolus injection in cancer chemotherapy. Ann Intem Med 1983; 99: 823–833
   PubMed Web of Science ®Google Scholar
• Syracuse KC, Greco WR. Comparison between the method of Chou and Talaly and a new method for the assessment of the combined effects of drugs: A Monte Carlo simulation study. Proc Biopharm Sect. Am Stat Assoc, Alexandria, VA 1988; 226–231
   Google Scholar
• Carter WH, Jr, Wampler GL, Stablein DM. Regression Analysis of Survival Data in Cancer Chemotherapy. Marcel Dekker, New York 1983
   Google Scholar
• Berenbaum MC. What is synergy?. Pharmacol Rev 1989; 41: 93–141
   PubMed Web of Science ®Google Scholar
• Greco WR, Park HS, Rustum YM. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosyicytosine. Cancer Res 1990; 50: 5318–5327
   PubMed Web of Science ®Google Scholar
• Sondak VK, Korn EL, Morton DL, Kern DH. Testing chemo-therapeutic combinations in the human tumor colony-forming assay. J Surg Oncol 1988; 37: 156–160
   PubMed Web of Science ®Google Scholar